Back

Antengene starts Phase III CLINCH-3 trial of ATG-022 in China

Verifying
  • Antengene dosed China’s first patient in the Phase III CLINCH-3 study of ATG-022.
  • ATG-022 recorded a 46.7% overall response rate at its 1.8 mg/kg RP2D.
  • CLINCH-3 is planned to expand into a multi-regional clinical trial.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Antengene starts Phase III CLINCH-3 trial of ATG-022 in China - CoinPost Terminal